Utz Brands
UTZ
$14.30
-0.14%
Utz Brands, Inc. is a U.S.-based manufacturer of branded salty snacks, producing potato chips, tortilla chips, pretzels, cheese snacks, party mixes, pork skins, popcorn, and dips under flagship brands including Utz, On The Border, Zapp's, and Boulder Canyon, alongside regional labels such as Golden Flake, Hawaiian, Bachman, and Tim's Cascade. The company operates in the Consumer Defensive sector within the Packaged Foods industry, positioning itself as a scaled but sub-national challenger to dominant players like PepsiCo's Frito-Lay and Campbell's Snyder's-Lance, with a distribution network that also carries select third-party brands. The dominant investor narrative has been transformed by the July 21, 2026 announcement of a $2.9 billion take-private deal, which triggered an 89% single-day surge in the share price and effectively converted the equity story from a margin-recovery turnaround into a merger-arbitrage situation. Attention now centers on deal completion risk, regulatory clearance, and the narrow spread between the market price and the implied transaction value, while the underlying business continues to post thin margins and modest low-single-digit revenue growth.…
UTZ
Utz Brands
$14.30
Related headlines
Investment Opinion: Should I buy UTZ Today?
The synthesized recommendation is Hold, with a clear thesis that the stock is now a merger-arbitrage situation offering negligible return potential and asymmetric downside risk. The analyst consensus average target price of $14.3125 implies just +0.09% upside from the current price of $14.30, and the recommendation field is reported as "none," consistent with analysts suspending traditional ratings pending deal completion. Four firms downgraded to Neutral or Equal Weight within days of the take-private announcement, including Piper Sandler, DA Davidson, Barclays, and Stephens & Co., confirming that the investment case is no longer a fundamental growth story.
Supporting evidence for the Hold rating includes the forward PE of 17.13x, which is below the 18-22x range for branded snack peers, and the PS ratio of 0.63x, which is roughly 60-75% below the sector norm of 1.5-2.5x. However, these discounts are justified by UTZ's inferior profitability, with a net margin of 0.056% versus sector norms of 8-12%, and elevated leverage at 1.64x debt-to-equity. Revenue growth of just 1.39% year-over-year and negative Q2 2026 free cash flow of -$1.9 million further undermine the standalone case. The implied upside to the analyst high target of $15.00 is only 4.9%, which would require either a raised bid or a competing offer that has not materialized.
The biggest risks that could invalidate the Hold rating are a deal break, which would likely send the stock down 44-51% toward the pre-deal range of $7.00-$8.00, and a deterioration in standalone fundamentals that would make the current price unsustainable even with deal optimism. This Hold would upgrade to Buy only if the stock traded significantly below the deal price, offering a favorable risk-reward spread, or if a competing bid emerged above $15.00. It would downgrade to Sell if regulatory or financing hurdles emerged that materially reduced deal-completion probability. Relative to its own history, the stock is trading at the very bottom of its historical PS band, but that discount reflects the market's prior loss of confidence in the standalone equity story rather than a genuine value opportunity.
Sign up to view all
UTZ 12-Month Price Forecast
The forward-looking view is neutral with high confidence because the stock is now a merger-arbitrage vehicle with a binary outcome. The base case, with 70% probability, sees the deal closing and the stock trading in a tight range around $14.00-$14.50, offering essentially zero return. The bull case, at 15% probability, could see a modest bump to $15.00 if a competing bid emerges, while the bear case, also at 15% probability, would trigger a 44-51% decline toward the pre-deal range of $7.00-$8.00. The risk-reward is asymmetric to the downside: investors are risking a 44-51% loss for a potential 0-5% gain. I would upgrade to bullish only if the stock traded significantly below the deal price, offering a favorable spread, or if a competing bid emerged above $15.00. I would downgrade to bearish if regulatory or financing hurdles emerged that materially reduced deal-completion probability.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Utz Brands's 12-month outlook, with a consensus price target around $14.31 and implied upside of +0.1% versus the current price.
Average Target
$14.31
0 analysts
Implied Upside
+0.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$14 - $15
Analyst target range
Eight analysts cover UTZ, and the consensus average target price is $14.3125, which implies just +0.09% upside from the current price of $14.30, essentially zero expected return. The target range is extraordinarily tight at $14.00 to $15.00, a spread of only $1.00 or roughly 7% of the current price, which is a hallmark of a stock trading on a known deal price rather than on fundamental dispersion. The consensus leans neutral by construction: the average target sits almost exactly at the market price, and the recommendation field is reported as "none," consistent with analysts suspending traditional ratings pending deal completion. The high target of $15.00 implies roughly 4.9% upside and would require either a raised bid, a competing offer, or a re-rating on standalone fundamentals that the current margin profile does not support. The low target of $14.00 implies about 2.1% downside and effectively prices in deal completion at or slightly below the current market level, with minimal cushion for break risk. Institutional ratings activity shows a clear and telling pattern: between July 16 and July 23, 2026, four firms downgraded to Neutral or Equal Weight from prior bullish stances, including Piper Sandler (Overweight to Neutral), DA Davidson (Buy to Neutral), Barclays (Overweight to Equal Weight), and Stephens & Co. (Overweight to Equal Weight), all within days of the take-private announcement. These downgrades are mechanical responses to the deal, as analysts remove upside ratings once a stock converges to the transaction price, and they confirm that the investment case is now a merger-arbitrage calculation rather than a fundamental growth story. The tight target spread signals high conviction about the deal outcome but offers negligible return potential, meaning the risk-reward from current levels is asymmetric to the downside if the transaction fails to close.
Bulls vs Bears: UTZ Investment Factors
The evidence currently favors the bear side in terms of risk-reward asymmetry, not because the business is deteriorating further, but because the stock price already reflects near-certain deal completion with essentially zero upside to the consensus target of $14.3125. The bull case rests almost entirely on the take-private deal closing at or above the current price, while the bear case highlights that any deal break would trigger a 44-51% decline toward the pre-deal range of $7.00-$8.00. The single most important tension is deal-completion probability: if the transaction closes, investors earn a negligible return; if it fails, they face catastrophic downside. The underlying business fundamentals—1.39% revenue growth, 25.87% gross margin, negative free cash flow, and 1.64x debt-to-equity—are too weak to support the current price on a standalone basis, meaning the entire investment case now hinges on a binary event.
Bullish
- Take-Private Deal Provides Hard Floor: The July 21, 2026 announcement of a $2.9 billion take-private deal caused an 89% single-day surge, and the stock has since traded in an extremely tight band between $14.04 and $14.32. With the current price at $14.30 and the 52-week high at $14.33, the market is pricing near-certain deal completion, and the $14.00 analyst low target implies only about 2.1% downside if the deal closes as expected.
- Deep Valuation Discount to Peers: UTZ trades at a forward PE of 17.13x and a PS ratio of 0.63x, versus typical packaged-food sector multiples of 18-22x forward earnings and 1.5-2.5x sales. The PS discount of roughly 60-75% below the sector norm made the company an attractive take-private candidate and provides a margin of safety if the deal were to break and the stock reverted toward peer multiples.
- Low Beta Limits Market Correlation: With a beta of 0.728, UTZ is roughly 27% less volatile than the broader market on a historical basis, which historically made it a defensive holding in a Consumer Defensive sector. This low beta, combined with the deal-driven price stability, means the stock is unlikely to suffer large drawdowns from broad market selloffs while the transaction is pending.
- Forward EPS Recovery Implies Margin Normalization: Consensus forward EPS of $0.88 versus trailing EPS of essentially zero ($0.00089) implies a dramatic earnings recovery driven by expected margin normalization. If UTZ were to achieve even a portion of this recovery on a standalone basis, the forward PE of 17.13x would represent a reasonable entry point for a branded snack company with stable revenue around $1.4-$1.5 billion annually.
Bearish
- Zero Upside to Analyst Consensus Target: The consensus average target price of $14.3125 implies just +0.09% upside from the current price of $14.30, essentially zero expected return. The target range is extraordinarily tight at $14.00 to $15.00, a spread of only $1.00 or roughly 7% of the current price, which is a hallmark of a stock trading on a known deal price rather than fundamental dispersion.
- Severe Margin Compression and Net Loss: Q2 2026 gross margin was 25.87%, down roughly 870 basis points from 34.58% in Q2 2025, and the company posted a net loss of $10.1 million with negative EPS of $0.11. The trailing operating margin of 6.85% and net margin of just 0.056% underscore how little profit the business retains, and the Q2 2026 operating loss of $5.5 million against $10.7 million of interest expense highlights that debt service is consuming essentially all operating earnings.
- Leveraged Balance Sheet with Negative Free Cash Flow: Debt-to-equity stands at 1.64x, the current ratio is 1.19, and Q2 2026 free cash flow was negative $1.9 million as operating cash flow of $11.7 million failed to cover $13.6 million of capital expenditure. Dividends paid of $5.6 million exceeded internally generated cash, and ROE of 0.11% and ROA of 0.065% are effectively zero, confirming the company is not generating meaningful returns on capital.
- Deal Break Risk with Massive Downside: If the take-private transaction fails to close, the stock would likely revert toward its pre-deal trading range of $7.00-$8.00, implying a decline of roughly 44-51% from the current $14.30 price. The 52-week low of $6.78 represents a 52.6% downside scenario, and the 50.9% maximum drawdown recorded over the period shows how violent the pre-deal decline had been.
UTZ Technical Analysis
UTZ is in a pronounced, event-driven uptrend that has completely reset its technical profile. The stock has gained 17.31% over the trailing year and 38.97% year-to-date, but the current price of $14.30 sits at approximately 99.8% of its 52-week range (low $6.78, high $14.33), meaning it is effectively pinned to the top of its annual band. This positioning reflects the July 21 take-private announcement rather than organic momentum, and the extreme proximity to the 52-week high signals that the market has already priced in deal completion with little room for upside optionality. The 50.9% maximum drawdown recorded over the period underscores how violent the pre-deal decline had been, making the current level a full round-trip recovery rather than a breakout into new territory. Recent momentum is decelerating sharply as the stock transitions from repricing to arbitrage. The 3-month change of 82.63% and 6-month change of 89.40% capture the deal-driven jump, but the 1-month change of just 0.56% shows the stock has gone essentially flat since mid-August, oscillating between $14.04 and $14.32 for nearly three months. This deceleration is not a bearish divergence in the traditional sense; it is the mechanical behavior of a stock trading at a fixed deal price, with the 1-month relative strength of -1.56% versus SPY reflecting the absence of further catalysts rather than distribution. The 1-year relative strength of +1.31% and 3-month relative strength of +79.50% confirm that virtually all outperformance was concentrated in the deal window. Key levels are now defined by the deal rather than by classical technical structure. Resistance is the 52-week high at $14.33, just $0.03 above the current $14.30 price, and a sustained break above it would imply either a raised bid or a competing offer. Support is anchored at the 52-week low of $6.78, but the more relevant near-term floor is the $14.00 analyst low target and the pre-deal trading range in the $7.00-$8.00 area, which would come back into play if the transaction collapses. With a beta of 0.728, UTZ is roughly 27% less volatile than the broader market on a historical basis, but that statistic is now largely stale because the stock's risk profile is binary and deal-dependent; position sizing should be governed by deal-completion probability, not by the historical beta.
Beta
0.73
0.73x market volatility
Max Drawdown
-49.7%
Largest decline past year
52-Week Range
$7-$14
Price range past year
Annual Return
+17.3%
Cumulative gain past year
| Period | UTZ Return | S&P 500 |
|---|---|---|
| 1m | +0.6% | +1.9% |
| 3m | +82.6% | +3.9% |
| 6m | +89.4% | +12.1% |
| 1y | +17.3% | +19.2% |
| ytd | +39.0% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTZ Fundamental Analysis
UTZ's revenue trajectory is stable but uninspiring, with the most recent quarter (ending June 28, 2026) delivering $371.8 million in revenue, up 1.39% year-over-year. The multi-quarter trend shows revenue oscillating in a narrow band: $361.3 million in Q1 2026, $342.2 million in Q4 2025, $377.8 million in Q3 2025, and $366.7 million in Q2 2025, implying a run-rate of roughly $1.4-$1.5 billion annually with no clear acceleration. The single reportable segment structure means there is no segment-level disclosure to identify pockets of strength or weakness, and the analyst consensus revenue estimate of $1.533 billion for the forward period implies only modest mid-single-digit growth at best. For a branded snack company competing against far larger rivals, this low-single-digit top-line growth is the central fundamental constraint and explains why the take-private deal, rather than organic re-rating, became the path to shareholder value. Profitability is thin and volatile, with the latest quarter posting a net loss of $10.1 million and negative EPS of $0.11, a sharp reversal from the $10.5 million profit and $0.12 EPS in the year-ago quarter. Gross margin in Q2 2026 was 25.87%, down from 34.58% in Q2 2025, a roughly 870 basis point compression that is the most alarming fundamental datapoint in the series, though the Q4 2025 gross margin of -6.60% appears distorted by accounting items and should be treated with caution. The trailing operating margin of 6.85% and net margin of just 0.056% underscore how little profit the business retains, and the Q2 2026 operating loss of $5.5 million against $10.7 million of interest expense highlights that debt service is consuming essentially all operating earnings. Balance sheet and cash flow metrics reveal a leveraged, cash-constrained business. Debt-to-equity stands at 1.64x, the current ratio is 1.19, and trailing free cash flow is only $51.1 million against a market cap near $903 million, implying a thin FCF yield of roughly 5.7%. The Q2 2026 cash flow statement shows operating cash flow of just $11.7 million against $13.6 million of capital expenditure, producing negative free cash flow of -$1.9 million, while dividends paid of $5.6 million exceeded internally generated cash. ROE of 0.11% and ROA of 0.065% are effectively zero, confirming that the company is not generating meaningful returns on its capital base and depends on refinancing and working-capital swings to fund operations.
Quarterly Revenue
$371800000.0B
2026-06
Revenue YoY Growth
+1.4%
YoY Comparison
Gross Margin
25.9%
Latest Quarter
Free Cash Flow
$51100000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTZ Overvalued?
Because UTZ's trailing net income is marginally positive but effectively zero (EPS of $0.00089), the trailing PE of 1,133.7x is economically meaningless, so the forward PE of 17.13x is the appropriate primary metric, supplemented by the PS ratio of 0.63x and EV/Sales of 1.97x. The enormous gap between the trailing PE (1,133.7x) and forward PE (17.13x) implies the market expects a dramatic earnings recovery, with consensus forward EPS of $0.88 versus essentially zero trailing EPS, a swing driven by expected margin normalization rather than revenue growth. The PEG ratio of -11.91 is negative and therefore not interpretable, reflecting the near-zero trailing earnings base rather than a genuine growth signal. On peer comparison, UTZ's forward PE of 17.13x and PS of 0.63x sit at a discount to typical packaged-food sector multiples, where branded snack peers often trade at 18-22x forward earnings and 1.5-2.5x sales; the PS discount is especially stark at roughly 60-75% below the sector norm. This discount is justified by UTZ's inferior profitability (net margin 0.056% vs. sector norms of 8-12%), elevated leverage (debt-to-equity 1.64x), and low-single-digit growth, and it is precisely this valuation gap that made the company an attractive take-private candidate. Against its own history, the current PS of 0.63x is dramatically below the 1.86x-4.37x range seen from 2021 through mid-2026, placing it at the very bottom of its historical band, while the PB ratio of 1.27x is near the low end of its 0.97x-2.26x multi-year range. The market is therefore not pricing optimistic standalone expectations; it is pricing a deal, and the historical compression in multiples reflects the market's prior loss of confidence in the standalone equity story.
PE
1133.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 10x~92x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.6x
Enterprise Value Multiple
Investment Risk Disclosure
UTZ faces significant financial and operational risks that are masked by the pending take-private deal. The company posted a Q2 2026 net loss of $10.1 million with negative EPS of $0.11, a sharp reversal from the $10.5 million profit and $0.12 EPS in the year-ago quarter. Gross margin compressed roughly 870 basis points year-over-year to 25.87%, and the Q2 2026 operating loss of $5.5 million against $10.7 million of interest expense shows that debt service consumes essentially all operating earnings. With debt-to-equity at 1.64x, a current ratio of 1.19, and trailing free cash flow of only $51.1 million against a market cap near $903 million, the company is cash-constrained and depends on refinancing and working-capital swings to fund operations. The dividend payout ratio of 27.9% and dividends paid of $5.6 million exceeding internally generated cash in Q2 2026 further strain liquidity.
Market and competitive risks are substantial for a sub-national challenger in the packaged foods industry. UTZ competes against far larger rivals like PepsiCo's Frito-Lay and Campbell's Snyder's-Lance, and its low-single-digit revenue growth of 1.39% year-over-year underscores its inability to gain meaningful share. The stock's beta of 0.728 historically made it less volatile than the market, but that statistic is now stale because the risk profile is binary and deal-dependent. Valuation compression risk is less relevant while the deal is pending, but if the transaction breaks, the stock could trade back toward its historical PS range of 1.86x-4.37x, which would imply a much lower price given current sales. Recent news highlights broader sector headwinds, including margin compression and international weakness at Lamb Weston, revenue declines at Medifast, and retail volume declines at Post Holdings, suggesting a challenging operating environment for packaged food companies.
The worst-case scenario is a deal break, which would likely trigger a rapid reversion to the pre-deal trading range of $7.00-$8.00. From the current price of $14.30, that implies a decline of roughly 44-51%, with the 52-week low of $6.78 representing a 52.6% downside. The 50.9% maximum drawdown recorded over the period shows how violent the pre-deal decline had been, and the stock's 1-month relative strength of -1.56% versus SPY reflects the absence of further catalysts rather than distribution. If the deal fails due to regulatory blockage or financing issues, the stock could quickly retest the $7.00-$8.00 area, and the analyst low target of $14.00 would become irrelevant as the market refocuses on standalone fundamentals. In this adverse scenario, an investor could lose 44-53% from the current price, with the 52-week low of $6.78 serving as a realistic floor.
FAQ
The most severe risk is deal-break risk: if the $2.9 billion take-private transaction fails to close, the stock would likely revert toward its pre-deal range of $7.00-$8.00, implying a 44-51% decline from the current $14.30 price. The second major risk is financial fragility, with Q2 2026 posting a net loss of $10.1 million, negative free cash flow of -$1.9 million, and debt-to-equity of 1.64x, meaning the company depends on refinancing and working-capital swings to fund operations. The third risk is competitive pressure from far larger rivals like PepsiCo's Frito-Lay and Campbell's Snyder's-Lance, which limits UTZ's pricing power and explains its 1.39% revenue growth. The fourth risk is margin compression, with gross margin falling roughly 870 basis points year-over-year to 25.87% in Q2 2026, which could worsen if input costs rise or promotional activity intensifies. Ranked by severity, deal-break risk is the most immediate and catastrophic, followed by financial fragility, competitive pressure, and margin compression.
The 12-month forecast is divided into three scenarios: a base case with 70% probability sees the deal closing and the stock trading in a tight range of $14.00-$14.50, offering essentially zero return; a bull case with 15% probability sees a competing bid or raised offer pushing the stock to $14.50-$15.00, representing up to 4.9% upside; and a bear case with 15% probability sees the deal failing and the stock falling to $6.78-$8.00, a decline of 44-51%. The most likely scenario is the base case, which assumes the deal receives all necessary regulatory approvals without material delays and no competing bid emerges. The key assumption behind the base case is that the acquirer maintains its financing commitments and UTZ's standalone operations remain stable with revenue growth around 1-2%. The forecast is highly binary and depends almost entirely on deal-completion probability rather than on fundamental business performance.
UTZ appears undervalued on traditional metrics, with a forward PE of 17.13x and a PS ratio of 0.63x, compared to typical packaged-food sector multiples of 18-22x forward earnings and 1.5-2.5x sales. However, this discount is justified by the company's inferior profitability, with a net margin of just 0.056% versus sector norms of 8-12%, and elevated leverage at 1.64x debt-to-equity. Against its own history, the current PS of 0.63x is dramatically below the 1.86x-4.37x range seen from 2021 through mid-2026, placing it at the very bottom of its historical band. The market is not pricing optimistic standalone expectations; it is pricing a take-private deal at approximately $14.30 per share. The trailing PE of 1,133.7x is economically meaningless due to near-zero trailing earnings, and the forward PE of 17.13x implies the market expects a dramatic earnings recovery to $0.88 per share. In reality, the stock is fairly valued relative to the deal price, with no margin of safety for standalone fundamentals.
From a risk-reward perspective, UTZ is not an attractive buy at the current price of $14.30 because the consensus analyst target of $14.3125 implies just +0.09% upside, while the downside risk from a deal break is 44-51% toward the pre-deal range of $7.00-$8.00. The stock is trading at 99.8% of its 52-week range, with the 52-week high at $14.33 just $0.03 above the current price, leaving virtually no room for capital appreciation. The investment case now hinges entirely on the $2.9 billion take-private deal closing, which is a binary event with no fundamental support from the standalone business, given 1.39% revenue growth and a net loss of $10.1 million in Q2 2026. For event-driven arbitrageurs with a high conviction on deal completion and a very short time horizon, the stock could be a modest holding, but for long-term investors, the risk-reward is unfavorable. A better entry point would be significantly below the deal price, offering a wider spread to compensate for deal-break risk.
UTZ is suitable only for short-term, event-driven investment, not for long-term holding. The stock's beta of 0.728 historically made it less volatile than the market, but that statistic is now stale because the risk profile is binary and deal-dependent. The company pays a dividend yield of 2.47% with a payout ratio of 27.9%, but the dividend is not well-covered by free cash flow, which was negative $1.9 million in Q2 2026. Earnings visibility is extremely low, with Q2 2026 posting a net loss of $10.1 million and revenue growth of just 1.39%. For long-term investors, the standalone business lacks the growth, margins, and balance sheet strength to justify a buy-and-hold strategy. A concrete suggested holding period for event-driven investors would be until the deal closes or fails, typically 3-9 months from the announcement date, with a strict stop-loss below $14.00 to limit downside if deal risk increases.